Aquavit Pharmaceuticals Adds New Patent To Its High-Tech Medical Portfolio
New York, NEW YORK, Sept 1, 2017
Aquavit Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has
issued a patent for Apollo Technology, System and Method for Personalized Injection Treatment (PITO-001: Patent # 9,675,519).
This follows Aquavit's European Patent (#EP2667965) issued by the European Patent Office (EPO) on July 27, 2016 and provides a
global protection for the first of its kind smart compounding technology and its big data application.
Aquavit’s iMicrotox™ (IMX-001) Study Receives IRB Approval
Las Vegas, NEVADA, Aug 31, 2017
Aquavit pharmaceuticals announced today that it has received a green light from the IRB, to conduct in-depth research
for microchannel application of neurotoxins in the peri-orbital region (IMT-121).
Aquavit Pharmaceuticals welcomes Tom Albright as its newest corporate advisory board member
New York, NEW YORK, Jul 7, 2017
Aquavit Pharmaceuticals welcomes Tom Albright as its newest corporate advisory board member. Mr. Albright has over
35 years of experience in the field of pharmaceutical, biologic, device and medical aesthetics.
Aquavit Pharmaceuticals, Inc. Granted Patent for Apollo™ (PITO-001):
System & Method for Personalized Injection Treatment by the USPTO
New York, NEW YORK, Jun 13, 2017
Aquavit Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has issued a patent
for Apollo Technology™, System and Method for Personalized Injection Treatment (Patent # 9,675,519).
October 21, 2016
Dear Valued Customers and Partners of Aquavit:
RE: Illegal Piracy Activities in Korea and China
It has come to our attention that an illegal Korean operator has been marketing pirated copies of AQUAGOLD® fine touch™.
You may find trade names such as Tappy Tok-Tok or Hydragold that appear similar to AQUAGOLD® fine touch™. However, these counterfeit
units are of sub-par quality and do not follow the same GMP standards our company requires. In addition, they are operating with
fake patents, certifications, and illegally using AQUAGOLD® trademarks to market in Asia and through the internet.
A.S.A.P. Inc. (Advanced Skin Application Platform) Becomes an Affiliate of Aquavit
Las Vegas, NEVADA, Oct 20, 2016
Aquavit has today signed on A.S.A.P. Inc., as one of its affiliate partners. A.S.A.P., Inc. is a Nevada
corporation dedicated to personalized skin health and solutions, and is developing and delivering technologies
that promote healthy looking skin.
Aquavit Pharmaceuticals Inc., Granted Patent for Apollo™ (PITO-001): System & Method for Personalized Injection Treatment in European Union
New York, NEW YORK, Jul 26, 2016
Aquavit Pharmaceuticals, Inc. announced that the European Patent Office (EPO) has issued patent for Apollo Technology™, System and Method for
Personalized Injection Treatment (Patent # EP2667965).
Message to AQUAGOLD customers
New York, NEW YORK, May 4, 2016
Dear Valued Customers and Partners of Aquavit:
RE: Illegal Piracy Activities in Korea and China
Aquavit Pharmaceuticals, Inc. is a global life science company focusing on cutting edge technology. One of our technologies, micro channeling device "AQUAGOLD"
is fully protected with worldwide perpetual licenses and overarching intellectual properties.
Dr. Mary Lupo Joins Aquavit Pharmaceuticals' Scientific Advisory Board
New York, NEW YORK, November 4, 2014
Aquavit Pharmaceuticals welcomes Mary Lupo, MD, FAAD as its newest Scientific Advisory Board member. Dr. Lupo
is a board-certified dermatologist who is internationally recognized for non-surgical skin rejuvenation.
Aquavit Pharmaceuticals Announces Official Launch of AQUAGOLD® fine touch™ at the 72nd Annual Meeting of the American Academy of Dermatology
Denver, COLORADO, March 23, 2014
Aquavit Pharmaceuticals, Inc., a New York-based technology-driven life science company, officially launched its cutting-edge device, AQUAGOLD® fine touch™ today at the annual meeting for the American Academy of Dermatology, the world's largest dermatology meeting.
AQUAGOLD® fine touch™is an innovative device incorporating microneedles smaller than a human hair to deliver a substantial volume of medication directly into the dermis.
Aquavit Pharmaceuticals Appoints David J. Goldberg as Chief Medical Officer; Launching Its First Commercial Product, AQUAGOLD® fine touch™ at AAD
New York City, NEW YORK, March 5, 2014
Aquavit Pharmaceuticals, Inc., a private high-tech life science company, announced today the appointment of David J. Goldberg, MD., JD. as its Chief Medical Officer. Dr. Goldberg is a renowned dermatologist and is recognized nationally and internationally
for his innovative work with skin lasers, cosmetic dermatology and facial rejuvenation techniques.
AQUAGOLD® fine touch™ showcased at 2014 South Beach Symposium
Miami Beach, FLORIDA, February 17, 2014
AQUAGOLD® fine touch™ was presented at the 2014 South Beach Symposium in Miami during a session on “What is New in Dermal Fillers". Dr. David Goldberg, Director, Skin Laser &
Surgery Specialists of NY/NJ and Clinical Professor and Director of Laser Research in the Department of Dermatology at the Mount Sinai School of Medicine...
AQUAGOLD® fine touch™ Presented at the 2014 International Master Course on Aging Skin (IMCAS) by Dr. David Goldberg
Paris, FRANCE, February 5, 2014
AQUAGOLD® fine touch™ was featured at the 2014 International Master Course on Aging Skin Conference (IMCAS) in Paris during a session on “Clinical Evaluation of the Efficacy and Tolerance of Combining a Topical Tightening Agent with Devices" .
Dr. David Goldberg, Director, Skin Laser & Surgery Specialists of NY/NJ and Clinical Professor and Director of Laser Research in the Department of Dermatology at the Mount Sinai School of Medicine, presented and discussed...
AQUAGOLD® fine touch™ featured at Winter Clinical Dermatology Meeting
Kohala Coast, HAWAII, January 19, 2014
AQUAGOLD® fine touch™ was featured at the 2014 Winter Clinical Dermatology Conference in Hawaii during a session on “New Procedures for the Aging Face”.
Dr. Mark Nestor, Director of the Center for Cosmetic Enhancement® and Director of the Center for Clinical and Cosmetic Research in Aventura, Florida...
Aquavit Pharmaceuticals Adds New Advanced Drug Delivery Technology to Product Portfolio
New York, NEW YORK, Nov 5, 2013
Aquavit Pharmaceuticals, Inc. has further extended its personalized drug delivery platform by signing a binding preliminary
agreement with Huons Co, Ltd. (KOSDAQ: 84110), a leading Korean pharmaceuticals company. The agreement formalizes the strategic
partnership between the parties and gives Aquavit the worldwide, perpetual, and unlimited license for global commercialization
of a cutting-edge drug-delivery system.
Aquavit Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
NEW YORK, March 4, 2013
Aquavit Pharmaceuticals Inc. has announced its newest addition to its management team, Dr. David Shafer.
He has been appointed Chief Medical Technology Officer and will be leading Aquavit’s R&D Medical Technology for Aquavit’s product pipeline.
Dr. B.G. Rhee Joins Aquavit’s Advisory Board
SEOUL & NEW YORK, January 21, 2013
We are pleased to announce that Dr. B.G. Rhee has signed on as a member of Aquavit Pharmaceutical’s Advisory Board.
The highly distinguished Dr. Rhee currently serves as the President of Green Cross Corp. (KOSPI: 006280), one of the leading biopharmaceutical companies in Korea.
Aquavit Pharmaceuticals Selects Uniquest for New High-Tech Medical Device Manufacturing
NEW YORK, December 12, 2012
Aquavit Pharmaceuticals, a privately held specialty pharmaceuticals and medical device company, has signed a term sheet with Uniquest Corporation (KOSPI:077500)
for co-investment in the development, registration and manufacturing of Aquavit Pharmaceuticals’ PITO-001 and QVT-1009. The partnership will drive a breakthrough in personalized medicine with the use of advanced technologies.
Aquavit Pharmaceuticals and Uniquest sign MOU for Alliance Partnership
SEOUL & NEW YORK, October 8, 2012
Aquavit Life Sciences, Inc, a wholly owned subsidiary of Aquavit Pharmaceuticals, Inc, announces together with Uniquest Corporation (KOSPI:077500)
a Memorandum Of Understanding to form an Alliance Partnership for the development, registration and manufacturing of Aquavit Pharmaceuticals’ PITO-001.
Aquavit Pharmaceuticals forms Alliance Partnership with Accelrys
NEW YORK, September 21, 2012
Aquavit Pharmaceuticals, Inc. and Accelrys Software Inc. (NASDAQ: ACCL), a leader in scientific innovation lifecycle management software,
have formed an alliance partnership towards the development of Aquavit’s PITO-001 and MAV-403 products.
Aquavit and Green Cross sign Strategic Collaboration MOU on IBX-001 Product Development and Commercialization in Asia
SEOUL & NEW YORK, August 8, 2012
Aquavit Pharmaceuticals, Inc. and Green Cross Corp. (006280:Korea SE), a leading biotechnology company in South Korea, signed a Memorandum of Understanding (MOU) towards establishing their strategic collaboration
surrounding the development and commercialization of Aquavit’s IBX-001 in Asia.
Video Interview with Dr Steven Fagien
NEW YORK, April 11, 2012
In a featured web article for the University of Florida, Dr. Steven Fagien was put under the Alumni Spotlight. Originally, philanthropic treatments had inspired him to
become an oculoplastic cosmetic surgeon. Now he is a figurehead of the discipline.
Dr. Steven Fagien appointed as Chairman, Scientific Advisory Board
NEW YORK, February 1, 2012
Steve Fagien MD has joined us as Aquavit as chairman of the Scientific Advisory Board.
As a world-class plastic surgeon he brings more than 25 years of clinical and development experience within the advanced field of facial aesthetics.
IMCAS Paris 2012
PARIS, FRANCE, January 30, 2012
Aquavit Pharmaceuticals, Inc. made its debut at IMCAS Paris on January 27, 2012. The company received a warm welcome from the European KOL community including Dr. Eric Auclair, President
of ISPRES and Dr. Gino Rigotti, President of SOFCEP. “We don’t have anything like it in Europe.
Berkeley HAAS Business School invites Aquavit CEO on Innovation
NEW YORK, September 2, 2011
Sobin Chang, CEO joined MBA students and faculty members at HAAS Business School, University of California at Berkley on September 1st, 2011 on the topic of “Innovation”.
She explored the concept of shared value – developing linkages between business strategies and product development – and how it can unleash the next wave of global growth and redefine capitalism within an organization. The event was followed by Q&As and luncheon.